Aura Biosciences (NASDAQ:AURA) Issues Earnings Results, Beats Estimates By $0.02 EPS

Aura Biosciences (NASDAQ:AURA) released its quarterly earnings results on Tuesday. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Price Performance

Shares of NASDAQ AURA traded down $0.14 during trading on Wednesday, hitting $10.51. 19,066 shares of the company were exchanged, compared to its average volume of 175,060. The firm’s fifty day moving average price is $9.69 and its 200 day moving average price is $8.49. The company has a market cap of $521.40 million, a price-to-earnings ratio of -6.06 and a beta of 0.33. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38.

Analyst Ratings Changes

Several brokerages have issued reports on AURA. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. HC Wainwright lifted their price objective on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Scotiabank upped their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. Finally, JMP Securities lifted their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Aura Biosciences currently has a consensus rating of “Buy” and a consensus price target of $23.00.

Insider Activity at Aura Biosciences

In related news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Aura Biosciences news, insider Los Pinos Elisabet De sold 24,992 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the sale, the insider now owns 329,847 shares in the company, valued at approximately $3,971,357.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now owns 121,132 shares in the company, valued at $1,193,150.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,259 shares of company stock worth $780,699 over the last 90 days. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.